Eric Donnenfeld, MD, from Ophthalmic Consultants of Long Island, discusses the importance of the Xdemvy FDA approval in treating patients with Demodex blepharitis.
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, discussed how treatment for Demodex blepharitis and Demodex mites will change with the recent approval of Xdemvy.
Transcript
How will the approval of Xdemvy change the way that Demodex mites and Demodex blepharitis are treated?
So it's very exciting that Xdemvy, the generic name is lotilaner, was approved by the FDA in late July. This is the first FDA-approved medication for treating Demodex blepharitis.
Demodex blepharitis is one of the most common diseases that we face on an everyday basis in our clinics and is responsible for ocular redness, irritation, many times with itching, and can participate in development of meibomian gland dysfunction. So, for the first time, we have a drug that can treat 1 of the most common diseases we see on a regular basis that impacts the ocular surface, and I feel that Xdemvy will have a profound effect on improving patient's ocular surface as well as improving their eyes and making them appear less red.
How are patients responding now that this treatment is available?
Xdemvy was recently approved, and it's been really a home run with a lot of interest in using Xdemvy for treating Demodex blepharitis. And this just makes sense, because we don't really have treatments that are available for this common disease. Early data shows that patients are responding to this treatment with Xdemvy, and I, personally, have had several patients who've had chronic, recrudescent inflammation, redness, and uncomfortableness in their lids who have responded beautifully to the use of this new medication.
So, it's wonderful that for the first time we have a drug that can actually treat one of the most common diseases we see in our clinic on a daily basis.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More